Search | Clinical Trials Finder

Conditions: Gestational Diabetes Mellitus in Pregnancy, Type 2 Diabetes
Interventions: OneTouch Reveal application; Behavioral
Lead sponsor: Carolyn Zahler-Miller; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Kidney Disease, Chronic
Interventions: BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 41
States / cities: Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more

Conditions: Diabetes, Gestational
Interventions: Misoprostol, Placebo; Drug · Dietary Supplement
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Fasiglifam, Placebo, Antihyperglycemic therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more

Conditions: Type2diabetes, Diabetic Kidney Disease
Interventions: Investigational Product - MIB 626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Diabetic Kidney Disease
Interventions: TMX-049, Placebo; Drug
Lead sponsor: Teijin America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 55
States / cities: Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more

Conditions: Diabetic Nephropathies
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 823 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more

Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Diabetic Nephropathies
Interventions: BI 685509, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Huntsville, Alabama • La Mesa, California • Los Gatos, California + 19 more

Conditions: Gestational Diabetes Mellitus in Pregnancy
Interventions: Continuous Glucose Monistor; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Nephropathy
Interventions: Sevelamer Carbonate, calcium carbonate; Drug
Lead sponsor: Gary Striker; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Diabetes, Kidney Disease, Hypertension
Interventions: losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Macrosomia, Fetal
Interventions: education tool, no additional information; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nervous System, Diabetic Kidney Disease, Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy
Interventions: Staff -Educational training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
Interventions: QRX-3; Drug
Lead sponsor: Ebima Clifford Okundaye; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pasedena, Texas

Conditions: Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions: Pegloticase 8 MG/ML [Krystexxa]; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus Type 2
Interventions: Inspiratory Muscle Strength Training (IMST), Sham Training; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years to 40 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions: Insulin, Glyburide, Metformin; Drug
Lead sponsor: Maisa N. Feghali, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gestational Diabetes, Diagnoses Disease, Pregnancy in Diabetic, Glucose, High Blood
Interventions: Fasting before gestational diabetes screen, Per oral intake of food and drink; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes During Pregnancy
Interventions: High-Protein Beverage (Genius Gourmet Sparkling Protein Water), Standard Clear Liquid Diet, Continuous Glucose Monitoring (Abbott Freestyle Libre); Dietary Supplement · Other · Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetic Nephropathy, Endothelial Dysfunction
Interventions: flavonoids; Dietary Supplement
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 12 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Amarillo, Texas

Search by objective public record fields.

Mobile App Logging for Diabetes in Pregnancy

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NAD Augmentation in Diabetes Kidney Disease

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

Improving Patient Understanding of Macrosomia

Mechanisms of Diabetic Kidney Disease in American Indians

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Clinic to Community Connections - Broader Distribution

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Uric Acid Lowering Trial in Youth Onset T2D

Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes